BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  FDA

  AstraZeneca and Merck’s Lynparza Approved For Ovarian Cancer Just a Week After GSK’s Zejula

  The Lynparza approval isn’t as broad as the Zejula approval, with Lynparza not approved for use in patients with homologous recombination deficiencies.

  May 11, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  Biopharma Update on the Novel Coronavirus: May 11

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 11, 2020.

  May 11, 2020

   · 

  4 min read

   · 

  BioSpace Editorial Staff
• 

  BioMidwest

  Study Suggests Gene Therapy May One Day Help with Muscle Development

  A study published on May 8 in Science Advances by researchers at the Washington University School of Medicine in St. Louis suggested that gene therapy may be helpful for building strength and significant muscle mass quickly in the body.

  May 11, 2020

   · 

  3 min read

   · 

  Krystle Vermes
• 

  FDA

  Abbott Earns Emergency Use Authorization for Another COVID-19 Antibody Test

  Approval of Abbott’s latest antibody test comes days after the FDA tightened its rules regarding the regulatory requirement for them.

  May 11, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  NSF-funded Smartphone COVID-19 Diagnostic Test Could Put Testing in the Hands of the Public

  A smartphone diagnostic test for COVID-19 being developed by a University of Utah researcher holds the potential for quick, accurate testing without the need for individuals to go to a healthcare facility. A prototype may be ready within two to three months.

  May 11, 2020

   · 

  4 min read

   · 

  Gail Dutton
• 

  Business

  Dyno Explodes Out of Stealth Mode with $2 Billion in Deals with Biopharma Companies

  Dyno says that with its research-and-development and collaboration deals with biopharma companies, it is potentially eligible for more than $2 billion in upfront payments, research support, and various milestones and option fees.

  May 11, 2020

   · 

  3 min read

   · 

  Mark Terry
• 

  FDA

  FDA Approves Eli Lilly’s Precision Oncology Treatment Retevmo for Certain Lung and Thyroid Cancers

  Eli Lilly is moving quickly to get a newly-approved precision oncology treatment, Retevmo, for certain lung and thyroid cancers into the hands of patients.

  May 11, 2020

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Genentech Taps Broad Institute’s Aviv Regev to Head Research and Early Development Program

  Pharma veteran Michael Varney, Genentech’s head of Research and Development, will retire from the company at the end of July after spending 15 years with the company.

  May 11, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  MyoKardia’s Experimental HCM Treatment Mavacamten Hits All Primary and Secondary Endpoints in Phase III Study

  In Phase III EXPLORER-HCM clinical trial, mavacamten demonstrated a robust treatment effect and met all primary and secondary endpoints.

  May 11, 2020

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Oyster Point’s Varenicline Shows Improvement in Late-Stage Study for Dry Eye Disease

  The company expects to submit a New Drug Application to the U.S. Food and Drug Administration in the second half of this year, with plans, if approved, to launch the drug in the fourth quarter of 2021.

  May 11, 2020

   · 

  3 min read

   · 

  Mark Terry